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ACS = acute coronary syndrome 3 
CA = chronic anaemia  4 
CI = confidence interval 5 
GRACE score = Global Registry of Acute Coronary Events 6 
HAA = hospital-acquired anaemia 7 
HR = hazard ratio 8 
LVEF = left ventricular ejection fraction 9 
MACE = major adverse cardiovascular events 10 
MI = myocardial infarction 11 
PCI = percutaneous coronary intervention 12 
PPI = proton pump inhibitor  13 
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Discharge anaemia is common following acute coronary syndromes (ACS). However, it is unknown if chronic 4 
anaemia (CA) and hospital-acquired anaemia (HAA) are associated with similar outcomes. 5 
 6 
In this retrospective analysis of 4083 ACS admissions treated with percutaneous coronary intervention in 7 
Switzerland (SPUM-ACS registry), 1896 patients (46.4%) had discharge anaemia (CA: n=643[15.7%] vs. HAA: 8 
n=1253[30.7%]). Landmark analysis that matched patients with CA (n=504) and HAA (n=866) with non-anaemic 9 
patients found increased one-year major adverse cardiovascular events (cardiovascular mortality, myocardial 10 
infarction, stroke) among patients with CA (6.9% vs. 3.0%, HR 2.073, 95% CI 1.039- 4.134, p=0.039) and HAA 11 
(3.8% vs. 2.3%, HR 1.772, 95% CI 1.002-3.232, p=0.049). Only CA was associated with increased one-year all-12 
cause mortality (7.9% vs. 1.6%, HR 4.255, 95% CI 1.950-9.284, p<0.001). 13 
 14 
CA and HAA were associated with poor one-year cardiovascular outcomes. Only CA was associated with 15 
increased all-cause mortality suggesting that HAA and CA represent distinct subclinical entities. 16 
 17 
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Baseline anaemia is prevalent among patients presenting with acute coronary syndromes (ACS) and is strongly 3 
associated with increased mortality [1,2]. It is typically a chronic anaemia associated with older age and 4 
comorbidities such as diabetes mellitus, chronic heart failure, chronic kidney disease and cerebrovascular disease 5 
[1]. However, patients can also develop hospital-acquired anaemia (HAA) during admission with ACS through 6 
bleeding that complicates pharmacological and invasive therapies, as well as through haemodilution [3]. It has 7 
been shown to develop in over 50% of ACS patients and is associated with increased mortality  [4–6] . 8 
 9 
There is limited data available on the cardiovascular outcomes of patients with discharge anaemia following ACS. 10 
Furthermore, CA and HAA likely represent distinct pathophysiological groups, and it is unknown if these groups 11 
experience similar outcomes following ACS. 12 
 13 
We aimed to determine the relationship between discharge anaemia (CA and HAA) and one-year clinical 14 
outcomes among patients with ACS treated with percutaneous intervention (PCI). We performed a retrospective 15 
analysis of patients admitted with ACS to four university hospitals in Switzerland and compared the one-year 16 
outcomes of patients discharged with CA and HAA with those of patients discharged without anaemia.   17 
  18 
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Data was obtained from the SPUM-ACS (Special Program University Medicine - Acute Coronary Syndromes) 4 
registry, a cohort of consecutive patients admitted with ACS to four university hospitals in Switzerland. All 5 
patients were aged 18 years or over. The only exclusion criteria were: severe physical disability, inability to 6 
comprehend the study or life expectancy of less than 1 year (for non-cardiac reasons). Further details of this 7 
registry have been reported previously [7]. For the present study, patients hospitalised between 2009 and 2017 8 
who received PCI were selected. The World Health Organisation thresholds were used to define anaemia as a 9 
haemoglobin <130 g/l in men and <120 g/l in women. Patients were defined as having CA if they were anaemic 10 
on both admission and discharge. Patients without anaemia on admission who were discharged with anaemia were 11 
defined as having HAA. 12 
 13 
Primary and secondary endpoints 14 
To eliminate the direct impact of bleeding on the endpoints, a landmark analysis was performed with a starting 15 
point of 7 days post-angiography. Events before this timepoint were not counted. The primary endpoint was 16 
defined as one-year major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, 17 
recurrent MI (using the universal definition of MI) and stroke. The secondary endpoint was defined as one-year 18 
all-cause mortality. The incidence of events during follow-up was ascertained by telephone consultation 30 days 19 
post discharge, and in a clinical face-to-face visit at one year. When patients could not be reached for the one-20 
year follow-up visit, medical information was obtained from primary care physicians, family members, hospital 21 
records or a registry office. Three certified cardiologists adjudicated all events. 22 
 23 
 24 
Statistical analysis 25 
Normally distributed, continuous variables are expressed as mean ± SD and compared using the 2-tailed Student 26 
t-test. Non-normally distributed continuous variables are expressed as a median with interquartile range and 27 
analysed using the Mann-Whitney U test. Comparisons between categorical variables were performed using the 28 
Pearson χ2 test. Missing values in baseline clinical characteristics were treated with multiple imputation in order 29 
to create five imputed datasets. Baseline and treatment characteristics as well as clinical endpoint rates are 30 
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 6 
presented for a single imputed dataset. Logistic and Cox regression analyses were performed on each imputed 1 
dataset before pooling of estimates as per Rubin’s Rules [8]. Multiple logistic regression was used to identify 2 
independent factors associated with HAA and CA. These models included the following covariates: age, sex, 3 
hypertension, diabetes, previous cardiovascular disease, valvular disease, chronic lung disease, active or previous 4 
malignancy, previous gastrointestinal bleeding, smoking status, body mass index (BMI), baseline use of 5 
anticoagulation/P2Y12 agent, heart rate, systolic blood pressure, ECG ischaemia, Killip class, type of ACS, 6 
stenting vs. balloon angioplasty only, presence of thrombus, P2Y12 agent prescribed.  A 1:1 propensity score-7 
matched analysis with a nearest-neighbour matching algorithm was used to manage intergroup differences in 8 
baseline and treatment variables prior to the sampling of the discharge haemoglobin level. Univariate Cox 9 
proportional hazards models and Kaplan-Meier analysis evaluated the impact of discharge anaemia on the clinical 10 
endpoints. Cubic spline functions were derived from multivariate Cox models of the unmatched populations and 11 
were plotted with four degrees of freedom. Among patients with a CRP value at the time of admission, a subgroup 12 
analysis was performed. A p-value <0.05 was defined as statistically significant. Statistical analysis was 13 
performed using R version 3.5.1.  14 
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Study population 3 
Among 4,083 patients, anaemia was present in 643 (16.0%) on admission and 1896 (46.4%) at discharge. Among 4 
those with discharge anaemia, 1253 patients (66.1%) had HAA compared with 643 patients (33.9%) with CA 5 
(Table 1). Only 9 patients with baseline anaemia were discharged with a normal haemoglobin value.  6 
 7 
Baseline clinical characteristics 8 
Missing values in baseline clinical characteristics were managed with multiple imputation (Online Table 1). The 9 
median discharge haemoglobin level was 139 g/l (IQR 133.00-146.00) in the non-anaemic (NA) group compared 10 
with 118.00 g/l (IQR 108.00-124.00) in the HAA group and 107.00 g/l (IQR 92.00-116.00) in the CA group 11 
(Table 2). Although all three groups (NA, CA, HAA) experienced a decrease in median haemoglobin level 12 
between admission and discharge, this was largest among HAA patients (NA: 9.00 g/l vs. HAA: 22.00 g/l vs. CA: 13 
8.00 g/l, p<0.001). Both HAA and CA groups differed significantly from the NA group for the majority of baseline 14 
factors (Table 1). Compared with the NA group, patients with discharge anaemia (HAA and CA) were 15 
significantly older, more often female, and had a higher prevalence of the majority of comorbidities including 16 
hypertension, diabetes mellitus, previous cardiovascular disease, valvular disease, chronic lung disease, 17 
previous/active malignancy, and previous gastrointestinal bleeding. With regards to clinical features, they also 18 
had higher GRACE scores, lower left ventricular ejection fractions (LVEF) and lower estimated glomerular 19 
filtration rates (eGFR). Conversely, the discharge anaemia groups had a significantly lower body mass index 20 
(BMI) and lower rates of smoking. 21 
 22 
Treatment factors 23 
In the unmatched population, the NA and discharge anaemia groups differed significantly with regards to a 24 
number of treatment factors (Table 2). In general, patients with discharge anaemia were more likely to have three 25 
or more stents implanted,TIMI grade flow <3 following PCI and be prescribed clopidogrel over prasugrel or 26 
ticagrelor. Although there was a high degree of compliance with ACS prescription guidelines, both discharge 27 
anaemia groups had fewer patients prescribed a statin. There was a higher rate of proton pump inhibitor (PPI) 28 
prescriptions in the discharge anaemia groups, and this was highest in the CA group. The HAA group had the 29 
highest occurrence of coronary thrombosis identified during angiography, with the CA group having the lowest. 30 
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 8 
The CA group also had a significantly lower proportion of patients with a percentage coronary stenosis of ≥95% 1 
at the site of the culprit lesion.  2 
 3 
Factors associated with the CA and HAA 4 
Multiple logistic regression applied to the unmatched population demonstrated that diabetes, chronic lung disease, 5 
chronic kidney disease, history of malignancy, and history of gastrointestinal bleeding were independently 6 
associated with CA. Additionally, low BMI and baseline use of oral anticoagulation and clopidogrel were 7 
independently correlated with CA. A history of malignancy was the only comorbidity independently associated 8 
with the development of HAA. However, HAA was also associated with baseline use of oral anticoagulation, 9 
raised GRACE score, elevated heart rate on admission, and the presence of thrombus during coronary 10 
angiography. 11 
 12 
Propensity-score matched analyses 13 
Chronic anaemia  14 
After 1:1 propensity score matching, 504 patients without discharge anaemia and 504 patients with CA were 15 
deemed equivalent in terms of all baseline and treatment factors, with the exception of baseline haemoglobin 16 
levels which were 147.00 g/l and 119.00 g/l, respectively (p<0.001) (Table 1 + 2). The median discharge 17 
haemoglobin level was 137 g/l in the NA group and 109 g/l in the CA group (p<0.001). Patients in the NA and 18 
CA groups experienced a similar decrease in haemoglobin level between admission and discharge (NA: 8.00 g/l 19 
(IQR 3.00-15.00) vs. CA 8.00 g/l (IQR 3.00-15.00), p=0.949). Baseline haemoglobin demonstrated a positive 20 
correlation with baseline eGFR in the CA group but not in the NA group (Online Figure 1). 21 
 22 
At one-year, the primary endpoint (MACE) occurred in 3.0% of patients in the NA group and 6.9% of patients in 23 
the CA group (HR 2.073, 95% CI 1.039- 4.134, p=0.039) (Figure 1). The CA group was also noted to have 24 
markedly higher rates of the secondary endpoint (all-cause mortality) compared with the NA group (7.9% vs. 25 
1.6%, HR 4.255, 95% CI 1.950-9.284, p<0.001). These findings were corroborated with Kaplan-Meier analyses 26 
(Figure 2A). 27 
 28 
Cubic spline functions demonstrated an exposure-response relationship, with rates of MACE and all-cause 29 
mortality increasing significantly with decreases in haemoglobin level below 120 g/l (Figure 3A). 30 
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Hospital-acquired anaemia 2 
After 1:1 propensity score matching, 866 patients with HAA and 866 patients without discharge anaemia 3 
presented no significant differences in baseline or treatment factors (Table 1 + 2). The median baseline 4 
haemoglobin value was 143.00 g/l in the NA group and 142.00 g/l in the HAA group (p=0.088). The median 5 
discharge haemoglobin value was 135 g/l in the NA group and 119 g/l in the HAA group (p<0.001). This 6 
corresponded to a median decrease in haemoglobin level between admission and discharge of 7.00 g/l (IQR 2.00-7 
12.00) in the NA group compared with 23.00 g/l (IQR 15.00-34.00) in the HAA group (p<0.001).  8 
 9 
At one-year, the primary endpoint occurred in 2.3% of patients in the NA group compared with 3.8% of patients 10 
in the HAA group (HR 1.772, 95% CI 1.002-3.232, p=0.049) (Figure 1). With regards to the secondary endpoint, 11 
similar rates were noted in the NA and HAA groups (1.3% vs. 1.8%, HR 1.452, 95% CI 0.647-3.628, p=0.363). 12 
These findings were confirmed with Kaplan-Meier analyses (Figure 2B).  13 
 14 
Cubic spline functions suggested an exposure-response relationship between discharge haemoglobin and MACE, 15 
with rates of MACE increasing with decreases in haemoglobin below 120 g/l (Figure 3B). However, there was 16 
no clear association between discharge haemoglobin and all-cause mortality. 17 
 18 
Medication compliance at one-year 19 
At one-year, compliance with ACS prescription guidelines was similar among surviving NA and discharge 20 
anaemia patients, including similar rates of aspirin and P2Y12 agent use (Online Table 2). 21 
 22 
C-reactive protein (CRP) in CA and HAA 23 
In a separate analysis, CRP values on admission were available for 1208 patients from the unmatched population. 24 
After propensity score matching, median CRP was slightly higher in the HAA group (NA: 2.10 mg/l (IQR 0.90-25 
5.50) vs. HAA: 2.80 mg/l (IQR 1.10-6.93), p=0.021) and even higher in the CA group (NA: 2.10 mg/l (IQR 0.93-26 
6.62) vs. CA: 3.80 mg/l (IQR 1.30-16.80), p=0.004). 27 
  28 
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The key findings of this retrospective analysis were: 3 
1) Discharge anaemia among ACS patients treated with PCI was common (46.4%). 4 
2) Both CA and HAA were independently associated with poorer one-year cardiovascular outcomes. 5 
3) Only CA was associated with increased one-year all-cause mortality. 6 
 7 
CA vs. HAA: different entities? 8 
Our results demonstrate that patients with CA are a vulnerable group with more comorbidities and significantly 9 
worse outcomes following ACS. They also suggest that patients who develop HAA represent a distinct subclinical 10 
group with a different risk profile.  11 
 12 
CA is often considered a marker of increasing age or the accumulation of comorbidities. However, this matched 13 
analysis demonstrates that CA is independently associated with significantly worse outcomes following ACS. A 14 
number of pathophysiological processes are responsible for the development of CA. Among patients ≥ 65 years 15 
old in the National Health and Nutrition Examination Survey (NHANES) III cohort, anaemia was explained by 16 
nutrient deficiency in one third, anaemia of chronic disease or chronic renal disease in another third, with the 17 
remaining third having unexplained anaemia [9]. CRP levels were also significantly higher among patients with 18 
anaemia of chronic disease.  In the present study, CRP levels too were found to be significantly higher among 19 
patients with CA. Additionally, baseline haemoglobin correlated positively with baseline eGFR among CA 20 
patients. One could therefore postulate that anaemia of chronic disease and chronic renal disease may in part 21 
underlie the anaemia in the CA group. 22 
 23 
Two important mechanisms that lead to the development of HAA are bleeding and haemodilution [3]. Bleeding 24 
can arise from antiplatelet and anti-thrombotic treatments prescribed following ACS, as well as from the 25 
catheterisation site used for PCI. Combined with a pre-existing bleeding tendency from underlying medical 26 
conditions or medications these patients may be at a particularly high risk of bleeding, leading to anaemia. In this 27 
study, the identification of malignancy and baseline oral anticoagulation as independent factors associated with 28 
the development of HAA provide support for this hypothesis. Additionally, the higher incidence of coronary 29 
thrombus in patients that went on to develop HAA may indicate that these were patients who were more likely to 30 
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have received adjunctive glycoprotein IIB/IIIA inhibitors, thus increasing their bleeding tendency further [10]. 1 
With regards to PPI usage, prescription rates at discharge in this study were similar to those in previously reported 2 
studies [11,12]. There was a higher rate of PPI prescriptions at discharge among patients who developed HAA, 3 
which could suggest a higher rate of gastrointestinal bleeding events in this group. Unfortunately, data on bleeding 4 
events was not available for analysis. Therefore, we can only speculate about the contribution of bleeding events 5 
to the development of HAA in this study. Interestingly, Salisbury et al. reported that in a cohort of ACS patients, 6 
of which over 70% underwent PCI, only 13.5% of those who developed HAA had any reported bleeding, 7 
emphasising that causes other than bleeding need to be considered in the development of HAA [6]. With regards 8 
to gastrointestinal bleeding, the latest guidance from the European Society of Cardiology now recommend the 9 
routine use of a PPI in combination with dual antiplatelet therapy [13]. Thus, it is likely that an increasing rate of 10 
PPI prescriptions in the future could reduce the contribution of gastrointestinal bleeding to the development of 11 
both HAA and CA [13]. 12 
 13 
Another important mechanism to consider is haemodilution, which can arise through the administration of IV 14 
fluids/medications during hospitalisation, as well as through fluid retention in acute heart failure following ACS 15 
[14,15]. While bleeding and haemodilution are likely to contribute to the development of HAA, further studies 16 
are needed to elucidate the exact mechanisms behind HAA following ACS. 17 
 18 
Why is anaemia associated with poor outcomes? 19 
Patients with anaemia are known to receive fewer evidence-based treatments following ACS [16]. This could, in 20 
part, explain their worse outcomes. However, in this analysis there were no significant differences in prescriptions 21 
between anaemic and non-anaemic, both at time of discharge and at one-year follow-up. This suggested that 22 
differences in pharmacological therapy did not explain the worse outcomes in discharge anaemia patients in this 23 
study, 24 
 25 
One mechanism that may drive poorer outcomes among anaemic patients is a worsening of the imbalance between 26 
myocardial oxygen supply and demand that is seen in coronary artery disease. This can be exacerbated by systemic 27 
vasodilatation and increased sympathetic tone seen in anaemic patients which in turn drive increased stroke 28 
volume and heart rate [17]. In the long-term, these haemodynamic changes can drive adverse myocardial 29 
remodelling [18,19]. In addition, two non-haemodynamic mechanisms may include impaired vascular healing and 30 
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chronic inflammation among anaemic patients. Anaemic patients have been shown to have reduced circulating 1 
endothelial progenitor cells following an ACS which could impair vascular healing  [20]. Another consideration 2 
is anaemia of chronic inflammation, a chronic inflammatory condition driven by an underlying inflammatory 3 
disease [9]. Anaemia of chronic inflammation is independently associated with increased rates of hospitalisation 4 
and mortality [9,21]. In the setting of ischaemic heart disease, inflammation is known to play an important role in 5 
all stages of atherothrombosis [22]. Furthermore, CRP has been shown to be an potent predictor of future vascular 6 
events, even when it lies in the high-normal range [23]. The present study noted raised CRP levels among the CA 7 
group, suggesting anaemia of chronic disease may have been present in at least some of these patients. 8 
 9 
Why do HAA and CA have different outcomes? 10 
One possible explanation is that patients with HAA were only affected by the haemodynamic changes associated 11 
with anaemia, whereas CA patients were also susceptible to non-haemodynamic complications such as chronic 12 
inflammation. Another consideration is the duration of anaemia following discharge. Patients with CA were more 13 
likely to have persistent anaemia during the follow-up period. Conversely, HAA may have resolved in some 14 
patients during follow-up as these patients were more likely to have normal haematopoietic function. Interestingly, 15 
Hasin et al. reported that among ACS patients discharged with anaemia, the outcomes of patients with resolving 16 
anaemia were similar to those without discharge anaemia [5].  Thus, it is plausible that the better outcomes in this 17 
group relate to recovery of haemoglobin levels in some of these patients.  18 
 19 
Time for intervention studies? 20 
There is sufficient evidence of the prognostic importance of anaemia following ACS to justify intervention 21 
studies. These could explore the impact of standardised testing of haematinics in all ACS patients with baseline 22 
anaemia in order to diagnose and treat deficiencies during the index admission. They could also evaluate the 23 
benefits of a lower blood transfusion threshold, particularly in the context of HAA. 24 
 25
Limitations 26 
This study is limited by its retrospective, observational design and thus these findings can only be considered as 27 
hypothesis generating. However, the SPUM-ACS registry represents a multicentre cohort of consecutive patients 28 
hospitalised with ACS. Given the very few exclusion criteria, we feel that the risk of bias is limited and that 29 
patients included in this study are likely representative of those encountered in routine clinical practice. The 30 
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 13 
prevalence of anaemia in this cohort was similar to previously reported figures, further suggesting that this 1 
population was representative [4]. Another limitation was the absence of data on bleeding events, blood 2 
transfusions and administration of IV fluids, all of which would have given better context to the discharge 3 
haemoglobin values. To tackle the absence of bleeding data, we performed a landmark analysis from day 7 post-4 
angiography in order to exclude events directly attributable to severe angiography-related bleeding rather than the 5 
longer-term effects of anaemia. Finally, there was no data available on haemoglobin levels following discharge, 6 
or whether patients received blood transfusions or other treatments for anaemia, thus it was not possible to evaluate 7 
the outcomes of patients who possibly had resolution of anaemia during the follow-up period.  8 
 9
Conclusions 10 
In an observational cohort of patients treated with PCI for ACS, both HAA and CA were associated with poorer 11 
one-year cardiovascular outcomes. However, CA and HAA likely represent distinct subclinical entities as only 12 
CA was associated with all-cause mortality. 13 
 14 
 15 
  16 
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HUMAN SUBJECTS/INFORMED CONSENT STATEMENT 1 
 2 
This project did not require approval by an ethics committee. Data collection for SPUM-ACS study was 3 
approved by Swiss ethics (Swiss Ethics Committees on research involving humans) involving the ethics 4 
committees of each local centre (Lausanne, Geneva, Bern and Zurich) and complies with all laws and 5 
international ethics guidelines outlined in the Declaration of Helsinki. All human patients provided written, 6 
informed consent. 7 
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ANIMAL STUDIES 1 
 2 
No animal studies were carried out by the authors of this study.  3 
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FIGURE LEGENDS 1 
 2 
 3 
Figure 1: Forest plot of one-year endpoints in patients without discharge anaemia compared with patients 4 
with: (A) chronic anaemia, and (B) hospital-acquired anaemia. For each propensity-matched analysis, event 5 
rates for each one-year clinical endpoint are presented for the non-anaemic and discharge anaemia groups along 6 
with the hazard ratio and p-value from the corresponding Cox proportional hazards model. MACE represents a 7 
composite of cardiovascular mortality, recurrent MI and stroke. CI = confidence interval; GRACE = Global 8 
Registry of Acute Coronary Events; MACE = major adverse cardiovascular events; MI = myocardial infarction.  9 
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Figure 2: Kaplan-Meier plots for propensity-score matched analyses of: (A) chronic anaemia, and (B) 1 
hospital-acquired anaemia.  Landmark timepoint from which events were recorded was set at 7 days post-2 
angiography (dotted line). For each endpoint, the p-value from the corresponding log-rank test is presented. 3 
MACE = major adverse cardiovascular events  4 
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Figure 3: Cubic spline functions demonstrating the impact of discharge haemoglobin value on one-year 1 
clinical endpoints for: (A) chronic anaemia, and (B) hospital-acquired anaemia. MACE = major adverse 2 
cardiovascular events  3 
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Online Figure 1: Association between baseline eGFR and baseline haemoglobin among patients with 1 
chronic anaemia. eGFR = estimated glomerular filtration rate.   2 
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Table 1: Baseline characteristics of unmatched and matched population. The unmatched population is 3 
stratified by type of discharge anaemia. For the matched analysis, patients with hospital-acquired anaemia (HAA) 4 
and chronic anaemia (CA) were matched to patients without discharge anaemia. Propensity-score matching (1:1) 5 
































































<0.001 193 (22.3) 
192 
(22.2) 








<0.001 455 (52.5) 
466 
(53.8) 








<0.001 144 (16.6) 
127 
(14.7) 









0.041 543 (62.7) 
553 
(63.9) 
0.654 298 (59.1) 298 (59.1) 1.000 







<0.001 95 (11.0) 89 (10.3) 0.697 89 (17.7) 87 (17.3) 0.934 







<0.001 108 (12.5) 99 (11.4) 0.553 113 (22.4) 102 (20.2) 0.442 
Previous CABG (%) 55 (2.5) 41 (3.3) 54 (8.4) <0.001 26 (3.0) 26 (3.0) 1.000 26 (5.2) 26 (5.2) 1.000 
Previous stroke (%) 39 (1.8) 28 (2.2) 43 (6.7) <0.001 20 (2.3) 17 (2.0) 0.740 22 (4.4) 17 (3.4) 0.514 
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<0.001 180 (20.8) 
166 
(19.2) 
0.435 160 (31.7) 160 (31.7) 1.000 
Valvular disease (%) 12 (0.6) 17 (1.4) 19 (3.0) <0.001 4 (0.5) 8 (0.9) 0.385 7 (1.4) 9 (1.8) 0.801 
Chronic lung disease 
(%) 
56 (2.6) 39 (3.1) 46 (7.2) <0.001 26 (3.0) 24 (2.8) 0.886 24 (4.8) 25 (5.0) 1.000 
Previous/current 
malignancy (%) 
122 (5.6) 100 (8.0) 
92 
(14.3) 
<0.001 64 (7.4) 60 (6.9) 0.780 62 (12.3) 57 (11.3) 0.696 
Previous GI bleed (%) 34 (1.6) 23 (1.8) 29 (4.5) <0.001 17 (2.0) 16 (1.8) 1.000 16 (3.2) 17 (3.4) 1.000 








0.003 229 (26.4) 
215 
(24.8) 








<0.001 344 (39.7) 
351 
(40.5) 













0.381 26.42 (3.92) 26.58 (4.49) 0.546 
Baseline haemoglobin 


























































































<0.001 742 (85.7) 
737 
(85.1) 
0.786 390 (77.4) 398 (79.0) 0.594 
Heart rate, beats-per-
















Systolic blood pressure, 
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<0.001 397 (47.3) 
388 
(46.2) 
0.679 266 (55.3) 281 (57.5) 0.539 








 756 (87.3) 
758 
(87.5) 
 421 (83.5) 417 (82.7)  





 78 (9.0) 70 (8.1)  52 (10.3) 56 (11.1)  
3 27 (1.2) 40 (3.2) 29 (4.5)  20 (2.3) 23 (2.7)  18 (3.6) 16 (3.2)  
4 13 (0.6) 69 (5.5) 34 (5.3)  12 (1.4) 15 (1.7)  13 (2.6) 15 (3.0)  








<0.001 280 (32.3) 
268 
(30.9) 








<0.001 566 (65.4) 
574 
(66.3) 
0.723 261 (51.8) 267 (53.0) 0.753 
Abbreviations: BMI = body mass index; CABG = coronary artery bypass graft; CAD = coronary artery disease; 1 
CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of 2 
Acute Coronary Events; IQR = interquartile range; LVEF = left ventricular ejection fraction; MI = myocardial 3 
infarction; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous intervention; SD = standard 4 
deviation; STEMI = ST-elevation myocardial infarction 5 
* Patients matched for: age, sex, diabetes, hypertension, hypercholesterolemia, previous MI, previous PCI, 6 
previous CABG, previous stroke, previous CVD, valvular disease, chronic lung disease, history of malignancy, 7 
history of gastrointestinal bleeding, family history of CVD, systolic blood pressure, heart rate, BMI, anaemia, 8 
Killip class, baseline eGFR, ECG ischemia, smoking, GRACE score, LVEF, type of ACS, PCI vs. balloon 9 
angioplasty only, percentage stenosis, number of stents, TIMI grade flow post-PCI, presence of coronary 10 
thrombus.   11 
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PCI - balloon dilatation 
only 
94 (4.3) 69 (5.5) 42 (6.5) 0.051 43 (5.0) 43 (5.0) 1.000 27 (5.4) 27 (5.4) 1.000 
Percentage stenosis (%)    <0.001   0.807   0.904 
<50% 9 (0.4) 1 (0.1) 1 (0.2)  0 (0.0) 1 (0.1)  0 (0.0) 1 (0.2)  


































Stent number (%)    <0.001   0.859   0.781 























≥3 76 (3.5) 84 (6.7) 35 (5.4)  50 (5.8) 43 (5.0)  22 (4.4) 21 (4.2)  
TIMI flow post-PCI (%)    <0.001   0.992   0.267 
0 10 (0.5) 23 (1.8) 6 (0.9)  7 (0.8) 6 (0.7)  6 (1.2) 1 (0.2)  
1 12 (0.6) 28 (2.2) 4 (0.6)  8 (0.9) 8 (0.9)  1 (0.2) 2 (0.4)  
2 41 (1.9) 43 (3.4) 19 (3.0)  28 (3.2) 29 (3.3)  14 (2.8) 15 (3.0)  
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Abbreviations: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CABG = coronary 1 
artery bypass graft; IQR = interquartile range; PCI = percutaneous intervention; SD = standard deviation; TIMI = 2 
thrombolysis in myocardial infarction; 3 
